Compare ESCA & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | SAVA |
|---|---|---|
| Founded | 1922 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.4M | 157.0M |
| IPO Year | N/A | N/A |
| Metric | ESCA | SAVA |
|---|---|---|
| Price | $12.81 | $3.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 18.7K | ★ 1.1M |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 4.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $241,540,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.00 | N/A |
| P/E Ratio | $13.81 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.41 | $1.15 |
| 52 Week High | $16.99 | $4.98 |
| Indicator | ESCA | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 52.90 |
| Support Level | $12.49 | $3.13 |
| Resistance Level | $13.09 | $3.38 |
| Average True Range (ATR) | 0.43 | 0.22 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 42.67 | 75.15 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are North America, Europe and others out of which a substantial part of the revenue is generated from North America region.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.